New from NCI |
People with Cancer Say Access to Their Clinical Notes Is Valuable |
| | A new federal rule mandates that all patients have access to the notes from their doctor visits. A new study on "open notes" finds that people with cancer and their doctors think this is a good idea. |
Obesity and Cancer: Pursuing Precision Public Health |
| | This section of the NCI Annual Plan & Budget Proposal for Fiscal Year 2022 explores the obesity epidemic and how it relates to cancer. Learn more about how obesity affects all aspects of the cancer continuum and how it can lead to poorer survival. |
Targeted Radiation Reduces Pain from Cancer Metastases in the Spine
For some people with painful spinal metastases from advanced cancer, a type of precise, high-dose radiation therapy may be an effective way to relieve the pain. Learn more about this treatment called stereotactic body radiation therapy, or SBRT. |
BRCA Gene Mutations: Cancer Risk and Genetic Testing
People who inherit harmful variants of the BRCA1 or BRCA2 gene have a higher risk of several cancers. This updated page describes the types of cancer that may result and the key role of genetic counseling and testing. |
Persistent Poverty Linked to Greater Risk of Dying from Cancer |
| | People who live in counties in the United States with persistent poverty are more likely to die from cancer than people in other counties, a new study shows. Persistent poverty counties are those with 20% or more of people living below the federal poverty level since 1980. |
Study of "Exceptional Responders" Yields Clues to Cancer and Treatment
An analysis of people with cancer who had unexpected and long-lasting responses to treatment revealed changes in the patients' tumors that may explain some of the lasting responses.
|
PDQ Updates |
Gastrointestinal Complications
We've revised this summary to include text about immunotherapy as a possible cause of diarrhea in people being treated for cancer. |
FDA Approvals |
New Approval for Breast Cancer
Food and Drug Administration approval for pembrolizumab (Keytruda) now includes treatment of triple-negative breast cancer that tests positive for the PD-L1 protein and has either returned and cannot be removed by surgery or has spread. |
No comments:
Post a Comment